Trials / Completed
CompletedNCT02777151
Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered REGN3470-3471-3479 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and immunogenicity of REGN3470-3471-3479 in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN3470-3471-3479 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-05-27
- Primary completion
- 2017-04-26
- Completion
- 2017-04-26
- First posted
- 2016-05-19
- Last updated
- 2018-02-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02777151. Inclusion in this directory is not an endorsement.